Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/39463

Title:	Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
Authors:	Halperin, Scott A Arribas, Jose R Rupp, Richard Andrews, Charles P Chu, Laurence Das, Rituparna Simon, Jakub K Onorato, Matthew T Liu, Kenneth Martin, Jason Helmond, Frans A View more
Keywords:	Ebola rVSVΔG-ZEBOV-GP safety vaccine View more
Mesh:	Adolescent Adult Aged Double-Blind Method Ebola Vaccines Ebolavirus Female Healthy Volunteers Hemorrhagic Fever, Ebola Humans Male Middle Aged Vaccination Vaccines, Synthetic Vesicular Stomatitis Viral Envelope Proteins Young Adult View more
Issue Date:	2017
Citation:	J. Infect. Dis..2017 06;(215)12:1789-1798
Abstract:	This study (NCT02503202) evaluated the safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP).
PMID:	28549145
URI:	https://hdl.handle.net/20.500.12530/39463
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos Hospitales > H. U. La Paz > Artículos

Files in This Item:

File	Description	Size	Format
PMC5853326.pdf		175.45 kB	Adobe PDF	View/Open